Duke Offshoot Trevena Closes $24M Funding Round to Support GPCR Drug-Discovery Tech | GenomeWeb
Trevena, a Duke University spinout developing drugs targeting G-protein coupled receptors, has closed a $24 million Series A financing round to continue developing its drug-discovery platform, the company said last week.
 
Trevena, whose platform is based in part on research conducted by a Duke scientist who helped invent the popular Transfluor GPCR assay, will look to leverage its relationship with its academic scientific founders to further develop its drug-discovery program, according to a company official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.